GPER1 and diabetes mellitus: Nevertheless, data have shown therapeutic benefits of the GPER-selective agonist G-1 in multiple disease models, ranging from multiple sclerosis to atherosclerosis to melanoma and pancreatic cancer, to diabetes and obesity.